GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

GoodRx (NASDAQ:GDRX – Free Report) had its price objective reduced by Citigroup from $7.00 to $6.25 in a research note issued ...

BofA lowered the firm’s price target on GoodRx (GDRX) to $4.25 from $4.50 and keeps an Underperform rating on the shares after the company ...

Citi analyst Daniel Grosslight lowered the firm’s price target on GoodRx (GDRX) to $6.25 from $7 and keeps a Buy rating on the shares as part ...

GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) dropped 8.4% during trading on Monday after Citigroup lowered their price target on the stock from $7.00 to $6.25. Citigroup currently has a buy ...

Rising drug prices remain a contentious issue in the US. Credit: Malte Mueller via Getty Images. At the 2025 JP Morgan Healthcare Conference, GoodRx’s recently appointed CEO Wendy Barnes highlighted ...

Analysts have set 12-month price targets for GoodRx Holdings, revealing an average target of $6.25, a high estimate of $7.00, and a low estimate of $6.00. Highlighting a 26.47% decrease, the current ...